Brief: Metacrine To Present Final Results From Phase 1 Trial Of MET642

Metacrine

11/03/2021 12:07

March 11 (Reuters) - Metacrine, Inc.  MTCR.O :
    * METACRINE TO PRESENT FINAL RESULTS FROM PHASE 1 TRIAL OF
MET642,
AN OPTIMIZED FXR AGONIST, AT THE 2021 NASH-TAG CONFERENCE
    * METACRINE, INC. - MET642 DEMONSTRATED BOTH AN ENCOURAGING
SAFETY
AND TOLERABILITY PROFILE IN HEALTHY VOLUNTEERS
    * METACRINE, INC. - MET642 DEMONSTRATED SUSTAINED FXR TARGET
ENGAGEMENT AFTER 14 DAYS OF DAILY ORAL DOSING
    * METACRINE, INC. - THERE WERE NO SERIOUS ADVERSE EVENTS,
AND ALL
TREATMENT-EMERGENT ADVERSE EVENTS WERE MILD TO MODERATE IN
SEVERITY FOR MET642
    * METACRINE, INC. - MET642 WAS NOT ASSOCIATED WITH INCREASED
LEVELS OF LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL OR REPORTS
OF PRURITUS

Source text for Eikon:  ID:nGNX5RzKFr 
Further company coverage:  MTCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))